S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Aemetis (AMTX) Stock Forecast, Price & News

-0.18 (-2.36%)
(As of 05/20/2022 06:55 PM ET)
Today's Range
50-Day Range
52-Week Range
597,600 shs
Average Volume
803,605 shs
Market Capitalization
$257.62 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive AMTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Aemetis and its competitors with MarketBeat's FREE daily newsletter.

Aemetis logo

About Aemetis

Aemetis, Inc. operates as a renewable natural gas and renewable fuels company in North America and India. It operates through three segments: California Ethanol, Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the acquisition, development, and commercialization of negative carbon intensity products and technologies that replace traditional petroleum-based products. It sells biodiesel primarily to government oil marketing companies, transport companies, resellers, distributors, and private refiners through its own sales force and independent sales agents, as well as to brokers who resell the product to end-users. The company also produces and sells ethanol; and wet distillers grains, distillers corn oil, and condensed distillers solubles to dairies and feedlots as animal feed. In addition, it produces dairy biogas; produces and sells high-grade alcohol and various feed products, as well as hand sanitizers; and researches and develops conversion technologies using waste feedstocks to produce biofuels and biochemicals. The company was formerly known as AE Biofuels, Inc. and changed its name to Aemetis, Inc. in November 2011. Aemetis, Inc. was founded in 2005 and is headquartered in Cupertino, California.


See More Headlines

Industry, Sector and Symbol

Industrial organic chemicals
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$211.95 million
Book Value
($3.72) per share


Net Income
$-47.15 million
Pretax Margin




Free Float
Market Cap
$257.62 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.18 out of 5 stars

Oils/Energy Sector

119th out of 373 stocks

Industrial Organic Chemicals Industry

12th out of 24 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -

Aemetis (NASDAQ:AMTX) Frequently Asked Questions

Is Aemetis a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aemetis in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aemetis stock.
View analyst ratings for Aemetis
or view top-rated stocks.

When is Aemetis' next earnings date?

Aemetis is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Aemetis

How were Aemetis' earnings last quarter?

Aemetis, Inc. (NASDAQ:AMTX) released its quarterly earnings data on Thursday, March, 10th. The specialty chemicals company reported ($0.03) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.24. The specialty chemicals company earned $64.36 million during the quarter, compared to analysts' expectations of $55.87 million. During the same quarter in the prior year, the business posted ($0.68) EPS.
View Aemetis' earnings history

What price target have analysts set for AMTX?

4 brokerages have issued twelve-month target prices for Aemetis' stock. Their forecasts range from $25.00 to $33.00. On average, they anticipate Aemetis' stock price to reach $29.67 in the next twelve months. This suggests a possible upside of 298.2% from the stock's current price.
View analysts' price targets for Aemetis
or view top-rated stocks among Wall Street analysts.

Who are Aemetis' key executives?
Aemetis' management team includes the following people:
What other stocks do shareholders of Aemetis own?
What is Aemetis' stock symbol?

Aemetis trades on the NASDAQ under the ticker symbol "AMTX."

Who are Aemetis' major shareholders?

Aemetis' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (9.05%), State Street Corp (5.86%), Vanguard Group Inc. (4.62%), Renaissance Technologies LLC (1.22%), Wellington Management Group LLP (1.12%) and Healthcare of Ontario Pension Plan Trust Fund (0.91%). Company insiders that own Aemetis stock include Andrew B Foster, Andrew B Foster, Francis P Barton, Francis P Barton, John R Block, John R Block, Sanjeev Gupta, Timothy Alan Simon and Todd Waltz.
View institutional ownership trends for Aemetis

Which institutional investors are selling Aemetis stock?

AMTX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Cutler Group LP, UBS Group AG, Renaissance Technologies LLC, DAVENPORT & Co LLC, Simplex Trading LLC, Group One Trading L.P., and Russell Investments Group Ltd.. Company insiders that have sold Aemetis company stock in the last year include Andrew B Foster, Francis P Barton, John R Block, and Sanjeev Gupta.
View insider buying and selling activity for Aemetis
or view top insider-selling stocks.

Which institutional investors are buying Aemetis stock?

AMTX stock was acquired by a variety of institutional investors in the last quarter, including Healthcare of Ontario Pension Plan Trust Fund, State Street Corp, BlackRock Inc., Jane Street Group LLC, Wellington Management Group LLP, Vanguard Group Inc., Baird Financial Group Inc., and L & S Advisors Inc.
View insider buying and selling activity for Aemetis
or or view top insider-buying stocks.

How do I buy shares of Aemetis?

Shares of AMTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aemetis' stock price today?

One share of AMTX stock can currently be purchased for approximately $7.45.

How much money does Aemetis make?

Aemetis has a market capitalization of $257.62 million and generates $211.95 million in revenue each year. The specialty chemicals company earns $-47.15 million in net income (profit) each year or ($1.460010) on an earnings per share basis.

How many employees does Aemetis have?

Aemetis employs 158 workers across the globe.

What is Aemetis' official website?

The official website for Aemetis is www.aemetis.com.

How can I contact Aemetis?

Aemetis' mailing address is 20400 STEVENS CREEK BLVD SUITE 700, CUPERTINO CA, 95014. The specialty chemicals company can be reached via phone at (408) 213-0940, via email at [email protected], or via fax at 408-252-8044.

This page was last updated on 5/23/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.